Novartis Fights Samsung's Bid To Nix Syringe Patents
Novartis AG has fired back at an attempt by a Samsung biotech subsidiary to invalidate five of its syringe patents for being "uninventive," arguing that the challenge to its technology falls...To view the full article, register now.
Already a subscriber? Click here to view full article